Description

(+)-3-[[(4-Fluorophenyl)Sulfonyl]Methylamino]-1,2,3,4-Tetrahydro-9H-Carbazole-9-Acetic Acid is a high-purity, synthetically derived chiral compound of significant interest in advanced pharmaceutical research and development. This molecule serves as a critical intermediate or building block for the synthesis of novel therapeutic agents, particularly those targeting the central nervous system. It is primarily utilized by pharmaceutical R&D laboratories, contract research organizations (CROs), and fine chemical manufacturers engaged in drug discovery programs.

Application

• Pharmaceutical Intermediate: Key chiral building block in the synthesis of novel drug candidates, particularly for neurological and psychiatric disorders.
• Biochemical Research: Used as a reference standard or ligand in pharmacological studies to investigate receptor binding and enzyme inhibition.
• Process Chemistry Development: Serves as a starting material or advanced intermediate for scaling up synthetic routes under Good Manufacturing Practice (GMP) conditions.
• Medicinal Chemistry: Enables structure-activity relationship (SAR) studies to optimize potency and selectivity of lead compounds.
• Custom Synthesis: Basis for the preparation of labeled analogs (e.g., deuterated, C14) for metabolism and pharmacokinetic studies.
• Academic Research: Utilized in university and institutional labs for exploratory chemistry and target validation projects.

Basic Information

Product Name	(+)-3-[[(4-Fluorophenyl)Sulfonyl]Methylamino]-1,2,3,4-Tetrahydro-9H-Carbazole-9-Acetic Acid
CAS No.	627865-18-3
Molecular Formula	C23H23FN2O4S
Molecular Weight	442.50 g/mol
Synonyms	(+)-3-[(4-Fluorobenzenesulfonyl)(methyl)amino]-1,2,3,4-tetrahydro-9H-carbazole-9-acetic acid; (3S)-3-[[(4-Fluorophenyl)sulfonyl](methyl)amino]-1,2,3,4-tetrahydro-9H-carbazole-9-acetic acid; UNII-8U8H8K5W6F; 8U8H8K5W6F; (S)-3-((4-Fluorophenylsulfonyl)(methyl)amino)-1,2,3,4-tetrahydrocarbazol-9-yl)acetic acid; Carbazole-9-acetic acid derivative; Chiral carbazole sulfonamide intermediate.
EINECS	Contact for details

Quality Control

Our production of this advanced pharmaceutical intermediate adheres to stringent quality systems. Each batch undergoes comprehensive analytical testing, including HPLC for chiral purity and assay, NMR for structural confirmation, and residual solvent analysis by GC. We provide full traceability and Certificates of Analysis (COA) detailing all specifications. Our quality commitment supports development from research to commercial scale, with the capability to meet GMP standards for drug substance manufacturing.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This compound is hygroscopic (moisture-sensitive); the container must be kept tightly sealed in a dry environment to prevent degradation. For long-term storage, consider using desiccants.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference
Assay (HPLC)	≥98.0%
Chiral Purity (Chiral HPLC)	≥99.0% ee
Water Content (KF)	≤0.5%
Residual Solvents (GC)	Meets ICH Q3C guidelines
Heavy Metals	≤20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.